MX2018001831A - Biomarcadores para el tratamiento de alopecia areata. - Google Patents

Biomarcadores para el tratamiento de alopecia areata.

Info

Publication number
MX2018001831A
MX2018001831A MX2018001831A MX2018001831A MX2018001831A MX 2018001831 A MX2018001831 A MX 2018001831A MX 2018001831 A MX2018001831 A MX 2018001831A MX 2018001831 A MX2018001831 A MX 2018001831A MX 2018001831 A MX2018001831 A MX 2018001831A
Authority
MX
Mexico
Prior art keywords
biomarkers
alopecia areata
treatments
treatment
incorporate
Prior art date
Application number
MX2018001831A
Other languages
English (en)
Inventor
Christiano Angela
Clynes Raphael
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MX2018001831A publication Critical patent/MX2018001831A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)

Abstract

La materia actualmente descrita se refiere a biomarcadores que permiten un mejor diagnóstico y pronóstico de la alopecia areata así como tratamientos efectivos para la enfermedad, incluyendo métodos que incorporan biomarcadores capaces de identificar subpoblaciones de pacientes que responderán a tales tratamientos y métodos que incorporan biomarcadores capaces de rastrear el progreso de tales tratamientos.
MX2018001831A 2015-08-14 2016-08-15 Biomarcadores para el tratamiento de alopecia areata. MX2018001831A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562205476P 2015-08-14 2015-08-14
PCT/US2016/047053 WO2017031067A2 (en) 2015-08-14 2016-08-15 Biomarkers for treatment of alopecia areata

Publications (1)

Publication Number Publication Date
MX2018001831A true MX2018001831A (es) 2018-09-06

Family

ID=58051338

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001831A MX2018001831A (es) 2015-08-14 2016-08-15 Biomarcadores para el tratamiento de alopecia areata.

Country Status (11)

Country Link
US (1) US20190072541A1 (es)
EP (1) EP3335041A4 (es)
JP (1) JP2018526362A (es)
KR (1) KR20180036788A (es)
CN (1) CN108449997A (es)
AU (1) AU2016308057A1 (es)
CA (1) CA2995750A1 (es)
IL (1) IL257509A (es)
MX (1) MX2018001831A (es)
RU (1) RU2018108831A (es)
WO (1) WO2017031067A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200332364A1 (en) * 2017-05-12 2020-10-22 Laboratory Corporation Of America Holdings Compositions and methods for detection of diseases related to exposure to inhaled carcinogens
EP3715471A1 (en) * 2019-03-29 2020-09-30 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Ahr signature marker set
CN110444248B (zh) * 2019-07-22 2021-09-24 山东大学 基于网络拓扑参数的癌症生物分子标志物筛选方法及系统
KR20230059846A (ko) 2021-10-20 2023-05-03 주식회사 에코덤 원형탈모증의 진단 또는 예후 평가를 위한 정보 제공 방법
KR20230059848A (ko) 2021-10-20 2023-05-03 주식회사 에코덤 Corynebacterium을 이용한 원형탈모증의 진단 또는 예후 판단을 위한 조성물
KR20230059847A (ko) 2021-10-20 2023-05-03 주식회사 에코덤 Staphylococcus caprae를 이용한 원형탈모증의 진단 또는 예후 판단을 위한 조성물
KR20230059849A (ko) 2021-10-20 2023-05-03 주식회사 에코덤 원형탈모증 환자를 위한 맞춤형 치료법의 선택방법
KR20230120594A (ko) * 2022-02-08 2023-08-17 주식회사 케라메딕스 탈당화 재조합 케라틴을 포함하는 탈모 치료용 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011082382A2 (en) * 2009-12-31 2011-07-07 The Trustees Of Columbia University In The City Of New York Methods for detecting and regulating alopecia areata and gene cohorts thereof
KR102027394B1 (ko) * 2010-11-02 2019-10-01 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 탈모 질환의 치료 방법

Also Published As

Publication number Publication date
WO2017031067A3 (en) 2017-03-30
IL257509A (en) 2018-04-30
EP3335041A4 (en) 2019-05-15
CA2995750A1 (en) 2017-02-23
KR20180036788A (ko) 2018-04-09
JP2018526362A (ja) 2018-09-13
US20190072541A1 (en) 2019-03-07
AU2016308057A1 (en) 2018-02-22
CN108449997A (zh) 2018-08-24
RU2018108831A (ru) 2019-09-16
EP3335041A2 (en) 2018-06-20
WO2017031067A2 (en) 2017-02-23

Similar Documents

Publication Publication Date Title
MX2018001831A (es) Biomarcadores para el tratamiento de alopecia areata.
PH12015501744A1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
EP3544483A4 (en) SYSTEM AND METHOD OF DISEASE DIAGNOSIS, TREATMENT AND PROGNOSIS DETERMINATION
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
WO2016109782A3 (en) Methods and compositions for detecting colorectal neoplasias
EA201591417A1 (ru) Новый способ диагностики депрессии и мониторинга эффективности терапии
NZ723884A (en) Methods of treating alzheimer’s disease
PH12018500578A1 (en) Methods of treating inflammatory diseases
NZ703411A (en) Use of markers in the diagnosis and treatment of prostate cancer
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
EP2996721A4 (en) Methods and compositions for prognosis, diagnosis and treatment of adam8-expressing cancer
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
CA2947310C (en) Microparticles for treating renal cell carcinoma
EA201890347A1 (ru) Антитела и исследования для обнаружения cd37
WO2013106766A3 (en) THERAPEUTIC INDICATIONS OF miR-1291
CN105189786A8 (zh) 用作治疗癌症的疗法的靶标的falz
EP3292218A4 (en) COMPOSITIONS AND METHODS FOR MONITORING, DIAGNOSIS, FORECASTING, DETECTION AND TREATMENT OF CANCER
WO2017095918A3 (en) Methods for treating cancer using rspo3 antagonists
UA86387U (ru) Способ оценки эффективности лечения больных с артериальной гипертензией, объединенной с метаболическим синдромом
WO2013119990A3 (en) Detection and treatment of cd30+ cancers
MX352296B (es) Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.
WO2013103792A3 (en) Method of treating cancer by administration of low levels of heat shock protein 70 (hsp70)
MA39718A (fr) Compositions et méthodes d'utilisation de celles-ci
AU2015903659A0 (en) Diagnosis, prognosis and treatment of cancer